The In uence of Prostate Volume on Prostate Cancer Detection
|
|
- Opal Page
- 5 years ago
- Views:
Transcription
1 European Urology Supplements European Urology Supplements 1 (2002) 35±39 The In uence of Prostate Volume on Prostate Cancer Detection Michael K. Brawer * Northwest Prostate Institute, Seattle, USA Abstract Objectives: The in uence of prostate volume on the positive yield of the systematic sector biopsy is logical and has been demonstrated in numerous reports. Methods: Literature on prostate biopsy was reviewed and a selection of articles made. Keywords used for the Medline search included: Prostate cancer, Biopsy, Diagnosis. Results: Sextant biopsies have the highest positive biopsy rate (40 g) in small prostates (<20 g), whereas in large prostate (80±90 cc) it drops to 10% only. Conclusions: The present paper reviews the in uence of total and peripheral volumes of the prostate on prostate cancer detection rates. # 2002 Elsevier Science B.V. All rights reserved. Keywords: Prostate volume; Prostate cancer; PSA In the last two decades, there have been signi cant changes in the approaches to the diagnosis of prostatic carcinoma. This has arisen owing to three technological advances: rst, the development of the springloaded biopsy device; second, transrectal ultrasound to guide biopsies; third, and most importantly, the widespread utilization of prostate speci c antigen as an indication for biopsy. Indeed, these three changes have resulted in staggering differences in the presentation of prostate cancer today [1]. Associated with these developments has been a signi cant modi cation in the biopsy approach. Initially, an abnormality on digital rectal examination resulted in biopsies speci cally directed either digitally or manually to the area of palpable abnormality was utilized. The development of transrectal prostate ultrasound resulted in a signi cant change. Initially it was felt that the most common presentation on most common sonographic appearance of prostate cancer was the hypoechoic peripheral legion [2±10]. Later, a number of authors suggested that many cancers occur in sonographically normal peripheral [11±16]. For example, we noted that in 2036 consecutive patients biopsied, cancer was detected in 25.5%. The cancer was found only in isoechoic sections in 14.4% of these men [42]. * Tel ; Fax: address: mbrawer@nwhsea.org (M.K. Brawer). It is now generally assumed that no sonographic appearance is de nitive for cancer, and thus biopsy approaches have adopted random nature. Other than concentrating on the peripheral where the majority of cancers arise, there is no other sonographically identi ed target to aim for. This realization made the prostate volume an essential component in our diagnostic strategy. This stems from the fact that if we have nothing to aim for, we are more likely to identify cancer in a smaller gland with an equivalent number of biopsies than in a larger gland. The rst observations in this regard actually stem from our initial inability to replicate the intriguing work suggesting the utility of prostate speci c antigen density. PSA density refers to the quotient of the serum PSA divided by the volume of the prostate gland [17]. Because of the fact that the largest component of prostate volume is benign prostatic hyperplasia, it makes intrinsic sense that normalization of total PSA by the gland volume may make PSA more speci c. A number of investigators carried out early work in this regard [17± 26]. As shown in Table 1, initial investigations demonstrated enhanced speci city with a minimal reduction in test sensitivity when PSA density was utilized [17,18,20,21,25,26]. Our own investigations were unable to recapitulate these ndings [24]. We theorized that a number of possible reasons to explain this apparent discrepancy. These included /02/$ ± see front matter # 2002 Elsevier Science B.V. All rights reserved. PII: S (02)
2 36 M.K. Brawer / European UrologySupplements 1 (2002) 35±39 Table 1 PSA results Author Biopsy Number of patients PSA (ng/ml) a Prostate volume (cc) a PSA density a Benson et al. [18] Positive (1.7) * 28.9 (14.6) * 0.30 (0.15) * Negative (1.8) 40.1 (20.2) 0.21 (0.11) Seaman et al. [19] Positive (1.70) 29.2 (14.2) * (0.147) * Negative (1.71) 42.2(21.8) (0.108) Brawer et al. [24] Positive (11.4) * 40.5 (16.6) 0.29 (0.41) Negative (5.0) 42.6 (25.6) 0.14 (0.14) Bazinet et al. [20] Positive (29.6) * 37.6 (21.4) * 0.63 (0.86) * Negative (8.1) 51.6 (27.3) 0.21 (0.25) Rommel et al. [21] Positive (21.6) * 42.7 (27.2) * 0.47 (0.11) * Negative (31.6) (0.09) Mettlin et al. [25] Positive (16.0) * 38.9 (16.4) 0.35 (0.5) * Negative (2.3), 33.5 (14.2) 0.08 (0.09) Ohori et al. [26] Positive (0.3±1320) b,* 28.1 (15.1±228.7) b,* 0.21 (0.009±39.3) b,* Negative (0.2±64.1) b,* 47.3 (13.3±332.6) b,* 0.09 (0.007±1.82) b,* a Data reported as mean (Standard Deviation). b Data reported as median (range) p < 0:05. * <0.05. differences in the accuracy in prostate ultrasound measurement, the size of the prostate in the study population, variability of the histologic makeup in the cohort of men being tested, as well as biopsy sampling error and PSA variability [24]. Subsequently,it became apparent that in most of the papers in which PSA density appeared to provide enhancement of PSA speci city, the glands harboring carcinoma were signi cantly smaller than in men without malignancy [17±21,26]. In our patients in which either there was no difference in the prostate volume between men without cancer. PSA speci city afforded no bene t [24]. It made us ponder whether it was not the performance of PSA density calculation that made a difference, but rather the fact that given an equal number of biopsy cores obtained, a larger gland would be more likely to give a false negative test result of biopsy, i.e. more cancers would be missed in the larger glandðthose with a lower PSA density (Fig. 1). In an effort to make density even more speci c, a number of authors evaluated the transition density where the serum PSA divided by the volume of the transition. Reports in this regard again were positive and indicated enhancement of test speci city [27,28]. We, too, were unable to reproduce these results [29] and again concluded that this was an artifact of missing cancer in the larger glands. In order to further evaluate this observation, we carried out an investigation studying the effect of prostate volume on the yield of needle biopsy [30]. In this study, we evaluated the cancer detection of six systematic sector biopsies performed because of either an abnormality on digital rectal examination or an elevation on serum PSA in 1057 men (Table 2). 326 were diagnosed with prostate cancer (30.8%). We observed a trend of decreasing cancer yield in men with larger glands (Fig. 2). Statistical tests utilizing an odds ratio analysis by yield was used to determine the cancer detection rate by quartile increase in total gland volume was utilized. No statistical relationship was observed between gland size and cancer yield when comparing the rst quartile to the second or third quartile. However, when comparing the smallest quartile to the largest Fig. 1. A schematic example of sampling error that could occur between larger and smaller prostate glands. Cancer in a larger gland is more likely to be missed by systematic sextant needle biopsy. (Taken from Nixon RG, Brawer MK, Re nements in serum prostate-speci c antigen testing for the diagnosis of prostate cancer. Recent Advances in Urology. 7 ed. London: Churchill Livingstone; 1998.)
3 M.K. Brawer / European UrologySupplements 1 (2002) 35±39 37 Table 2 Patient age, serum PSA, and total gland and peripheral volumes according to presence or absence of cancer on transrectal ultrasound guided prostate needle biopsy Mean S.D. (range) p-value Positive biopsy (326 pts.) Negative biopsy (731 pts.) Age (46±92) (31±73) Serum PSA (ng/ml) (0.6±386.0) (0.1±20.4) volume (cm 3 ) (10.5±139.4) (4.5±311.5) volume (cm 3 ) (1.4±93.2) (1.8±204.6) Table 3 Biopsy yield as a function of the total gland and peripheral volumes using odds ratio analysis Quartile 1 (265 pts.) Quartile 2 (264 pts.) Quartile 3 (264 pts.) Quartile 4 (264 pts.) Cut-off or less or less or less or less or less or less or less or less volume (cm 3 ) Yield (%) Odds ratio % CI 0.745± ± ± ± ± ±1.88 p-value Not significant Not significant Not significant Not significant Significant Significant quartile of patients, a signi cantly lower cancer detection rate was noted (odds ratio 1.5). We concluded that the positive yield of the systematic sector biopsy decreases signi cantly when total gland volume is greater than 55.6 cc (Table 3). These ndings were reproduced by the work of Karakiewicz et al. [31] as well as Uzzo et al. [32]. In the Karakiewicz investigation, 1974 men who had systematic sextant biopsies had decreasing yield of biopsy with increasing gland volume ( p < 0:001). The highest positive biopsy rate (39.6%) was recorded among prostates that were smaller than 20 cc. The lowest biopsy rate in his study (10.1%) was noted in those glands between 80 and 90 cc. Uzzo et al. [32] noted similar results. It has been widely reported that the absence of detection of cancer on the initial systematic six biopsy sector approach does not eliminate the possibility of missed cancer. Indeed, the literature is replete with Table 4 Prostate cancer detection rate with corresponding number of biopsy cores References Number of pts. Number of cores %Ca detection Eskew et al. [37] Reitbergen et al. [38] Nava et al. [39] Levine et al. [40] Fig. 2. Cancer detection rate as function of total gland volume. (Taken from Letran J, Meyer G, Loberiza F, Brawer M: The effect of prostate volume on the yield of needle biopsy. J Urol 160(5):1718±1721, 1998.) Brown et al. [41]
4 38 M.K. Brawer / European UrologySupplements 1 (2002) 35±39 articles indicating cancer detection in 20±40% of men with an initial negative biopsy [16,33,34]. This has resulted in a variety of strategies to enhance the yield of cancer by both increasing the number and the trajectory utilized and obtained in the biopsy. A number of authors have carried out investigations where they used a variety of number of needle biopsies and compared cancer yield detection. As shown in Table 4, all of these studies demonstrate increased cancer detection with increased number of cores obtained. We are unaware of any study which prospectively used prostate volume as a determinant of the number of cores obtained. This would provide the de nitive answer to the question whether the increased yield with more cores is a function of better sampling but this seems obvious. Our current biopsy methodology is to utilize ten cores with ve obtained from each side. We performed systematic sector biopsy as originally described by Hodge in the parasaggital plane between the lateral and middle third of each half of the prostate [35]. Two additional cores obtained from each side in an extreme lateral position to increase sampling of peripheral tissue extending into the anterior horn as suggested by Stamey [36]. It would seem prudent to utilize prostate volume as a factor in determining the need for repeat biopsy in a man with an initial negative prostate biopsy. References [1] Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974±1994. J Urol 1997;58(4):1427±30. [2] Lee F, Gray J, McCleary R. Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology and staging. Prostate 1985;7:117±29. [3] Lee F, Littrup PJ, Torp-Pederson ST, Mettlin C, McHugh TA, Gray JM. Prostate cancer: comparison of TRUS and DRE for screening. Radiology 1988;168:389±94. [4] Lee F, Torp-Pedersen ST, McLeary RD. Diagnosis of prostate cancer by transrectal ultrasound. Urol Clin North Am 1989;16:663±73. [5] Lee F, Torp-Pedersen ST, Siders DB, et al. Transrectal ultrasonography in the diagnosis and staging of prostatic carcinoma. Radiology 1989;170:609. [6] Lee FR, Gray JM, McLeary RD, et al. Prostatic evaluation by transrectal sonography: criteria for diagnosis of early carcinoma. Radiology 1986;158:91±5. [7] Cooner WH, Mosley RB, Rutherford J, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-speci c antigen. J Urol 1990;143:1146±54. [8] Rifkin MD. Endorectal sonography of the prostate: clinical implications. AJR 1987;148:1137±42. [9] Rifkin MD, Friedland GW, Shortliffe L. Prostatic evaluation by transrectal ultrasonography: detection of carcinoma. Radiology 1986; 158:85±90. [10] Watanabe H. Transrectal sonography: a personal review and recent advances. Scand J Urol Nephrol 1991;137:75±83. [11] Resnick MI, et al. Transrectal prostate ultrasonography-variability of interpretation. J Urol 1994;151(Suppl):503A. [12] Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, Walsh PC. Evaluation of transrectal ultrasound in the early detection of prostate cancer. J Urol 1989;142:1008±10. [13] Dahnert WF, Hamper UM, Eggleston JC, Walsh PC, Sanders RC. Prostatic evaluation by transrectal sonography with histopathologic correlation: the echopenic appearance of early carcinoma. Radiology 1986;158:97±102. [14] Salo JO, Rannikko S, Makinen J, Lehtonen T. Echogenic structure of prostatic cancer imaged on radical prostatectomy specimens. Prostate 1987;10:1±9. [15] Ellis WJ, Brawer MK. The signi cance of isoechoic prostatic carcinoma. J Urol 1994;152(6):2304±7. [16] Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J Urol 1995;153(5):1496±8. [17] Benson MC, Whang IS, Pantuck A, et al. Prostate-speci c density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815±6. [18] Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of PSA density to enhance the predictive value of intermediate levels of serum PSA. J Urol 1992;147:817±21. [19] Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD): role in patient evaluation and management. Urol Clin North Am 1993;20:653. [20] Bazinet M, Meshref AW, Trudel C, et al. Prospective evaluation of prostate-speci c antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994;43:44±51. [21] Rommel FM, Augusta VE, Breslin JA, et al. The use of PSA and PSAD in the diagnosis of prostate cancer in a community based urology practice. J Urol 1994;151:88±93. [22] Littrup PJ, Kane RA, Mettlin CJ, et al. Cost-effective prostate cancer detection: reduction of low-yield biopsies. Cancer 1994;74(12): 3146±58. [23] Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The value of screening tests in the detection of prostate cancer. Part I. Results of a retrospective evaluation of 1726 men. Urology 1995;46(6):773±8. [24] Brawer MK, Aramburu EAG, Chen GL, Preston SD, Ellis WJ. The inability of PSA index to enhance the predictive value of PSA in the diagnosis of prostatic carcinoma. J Urol 1993;150:369±73. [25] Mettlin C, Littrup PJ, Kane RA, et al. Relative sensitivity and speci city of serum PSA level compared with age-referenced PSA, PSA density and PSA change. Cancer 1994;74:1615±20. [26] Ohori M, Dunn JK, Scardino PT. Is prostate-speci c antigen density more useful than prostate-speci c antigen levels in the diagnosis of prostate cancer. Urology 1995;46:666±71. [27] Djavan B, Zlotta AR, Shariat S, Omar M, Schulman CC, Marberger M. Prostate speci c antigen density of the transition for early detection of prostate cancer. J Urol 1998;160(2):411±8. [28] Maeda H, Ishitoya S, Maekawa S, et al. Prostate speci c antigen density of the transition in the detection of prostate cancer. J Urol 1997;(Suppl):58A. [29] Lin DW, Gold MH, Ransom S, Ellis WJ, Brawer MK. Transition PSA density: lack of utility in prediction of prostatic carcinoma. J Urol 1998;160:77±82. [30] Letran J, Meyer G, Loberiza F, Brawer M. The effect of prostate volume on the yield of needle biopsy. J Urol 1998;160(5):1718±21. [31] Karakiewicz PL, Bazinet M, Aprikian AG, et al. Outcome of sextant biopsy according to gland volume. Urology 1997;49(1):55±9. [32] Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan ED. The in uence of prostatic size on cancer detection. Urology 1995;46:821. [33] Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate-speci c antigen levels. J Urol 1994;151:1571±4.
5 M.K. Brawer / European UrologySupplements 1 (2002) 35±39 39 [34] Roehrborn CG, Pickens GJ, Sanders JS. Diagnostic yield of repeated transrectal ultrasound-guided biopsies strati ed by speci c histopathologic diagnoses and prostate-speci c antigen levels. Urology 1996;47:347±52. [35] Hodge KK, McNeal SE, Terris MK, Stamey TA. Random systematic versus directed ultrasound-guided transrectal core biopsies of the prostate. J Urol 1989;142:71±5. [36] Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45(1):2±11. [37] Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157:199±203. [38] Reitbergen JBW, Kruger AEB, Kranse R, Schroder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology 1997;49:875±80. [39] Nava L, Montorsi F, Consonni P, Scattoni V, Guazonni G, Rigatti P. Results of a prospective randomized study comparing 6,12, and 18 transrectal ultrasound-guided sextant biopsies in patients with elevated PSA normal DRE and normal prostate ultrasound. Urology 1997;226:59A. [40] Levine MA, Melamed J, Ittmann M, Lepor H. Two consecutive sets of transrectal ultrasound (TRUS) guided sextant biopsies of the prostate for the diagnosis of prostate cancer. J Urol 1997;244(157): 64A. [41] Brown M, True LD, Ellis WJ, Brawer MK. Does increased number of ultrasound-guided prostate needle biopsies enhance the yield of the chance of nding carcinoma. Urol J 1997;157(4): 144A. [42] Brawer MK, Chetner MP. Ultrasonography of the prostate and biopsy. In: Walsh PC, Retik AB, Vaughan Jr ED, Wein AJ, editors. Campbell's urology, Vol. 3. 7th ed. Philadelphia: Saunders, 1998.
Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationTHE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 27 (3): 222-226, May - June, 2001 THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE
More informationor more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. of >10 ng/ml have prostate cancer [3], many other
BJU International (1999), 83, 34 38 Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? G.C. DURKAN
More informationONCOLOGY LETTERS 8: , 2014
1834 Systematic 12 and 13 core transrectal ultrasound or magnetic resonance imaging guided biopsies significantly improve prostate cancer detection rate: A single center 13 year experience GONG CHENG *,
More informationAre extended biopsies really necessary to improve prostate cancer detection?
(2003) 6, 250 255 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Are extended biopsies really necessary to improve prostate cancer detection? R Damiano*,1, R
More informationSocio-demographic profile of prostatic diseases in symptomatic patients: a prospective cross-sectional study
International Journal of Advances in Medicine Praveenkumar P et al. Int J Adv Med. 2015 May;2(2):138-143 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Research Article DOI: 10.5455/2349-3933.ijam20150512
More informationExtended 12-Core Prostate Biopsy Increases Both the Detection of Prostate Cancer and the Accuracy of Gleason Score
european urology xxx (2005) xxx xxx available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Extended 12-Core Prostate Biopsy Increases Both the Detection of Prostate
More informationISSN X (Print) Pradesh. *Corresponding author Dr. Ashish
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2015; 3(8B):2886-2890 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationUsing Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer
Using Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer Ethan J. Halpern 1 Stephen E. Strup 2 OBJECTIVE. We performed a prospective study to assess gray-scale and color and power
More informationComputer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd? 200613?12901295Original ArticleAdditional apical biopsy in prostatic gland
More informationUltrasonographically Guided Biopsy of the Prostate Gland
Review Article Ultrasonographically Guided Biopsy of the Prostate Gland Andrew L. Altman, MD, Martin I. Resnick, MD Abbreviations BPH, benign prostatic hyperplasia; PIN, prostatic intraepithelial neoplasia;
More informationRole of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53..46 Urological Oncology Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
More informationINTEROBSERVER VARIATION OF PROSTATIC VOLUME ESTIMATION WITH DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS WITH DIFFERENT EXPERIENCES
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS Vol. 30 (6): 466-471, November - December, 2004 INTEROBSERVER
More informationJMSCR Vol 05 Issue 03 Page March 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.135 Diagnosis of Carcinoma Prostate Based
More informationHistopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate
ORIGINAL ARTICLE Histopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate in Patients With Raised Serum Prostate Specific Antigen Prabha Rathour 1, Hetal Jani 2, Urvi Parikh 3, Hansa
More informationProstate Cancer 3/15/2017. CEUS of the Prostate. The Prostate Cancer Screening Dilemma Data. Incidence: 161,360 Deaths: 26,730
Prostate Cancer CEUS of the Prostate 2017 Data Incidence: 161,360 Deaths: 26,730 Third leading cause of cancer death in men (after lung & Professor of Radiology & Urology colon Ca) Co-Director, Jefferson
More informationFisher s exact test for contingency tables. A two-tailed p-value <0.05 was accepted as statistically significant.
BJUI A prospective, randomized trial comparing the Vienna nomogram to an eight-core prostate biopsy protocol Angus Lecuona and Chris F. Heyns Department of Urology, Tygerberg Hospital and University of
More informationEvaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate
Evaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate Pages with reference to book, From 360 To 363 Farkhanda Ghafoor,Shahzad Khan,Bilquis Suleman,Aman Ullah Khan ( Departments of
More informationThe Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
Research Article TheScientificWorldJOURNAL (2009) 9, 343 348 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.47 The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial
More informationAge-Specific Reference Ranges for PSA in the Detection of Prostate Cancer
Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer Review Article [1] April 01, 1997 By Edward P. Deantoni, PhD [2] PSA is the best tumor marker yet discovered. Age-specific reference
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationTWELVE CORE PROSTATE BIOPSY VERSUS SIX SYSTEMATIC SEXTANT BIOPSIES
Clinical Urology Brazilian Journal of Urology Vol. 28 (3): 207-213, May - June, 2002 Official Journal of the Brazilian Society of Urology TWELVE CORE PROSTATE BIOPSY VERSUS SI SYSTEMATIC SETANT BIOPSIES
More informationTransrectal ultrasound-guided biopsy for the diagnosis of prostate cancer
Transrectal ultrasound-guided for the diagnosis of prostate cancer Adrian Haşegan Clinica de Urologie, Spitalul Clinic Judeţean de Urgenţă Sibiu Facultatea de Medicină Sibiu Abstract Transrectal ultrasound-guided
More informationOwing to the widespread use of prostate specific antigen (PSA)
ORIGINAL RESEARCH Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation Moamen M. Amin, MD; Suganthiny Jeyaganth, MSc; Nader Fahmy,
More informationEnzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum
Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum FOR RESEARCH USE ONLY Store at 2 to 8 C. PROPRIETARY AND COMMON NAMES f-psa Enzyme Immunoassay
More informationDetection of prostate cancer by MR-ultrasound fusion guided biopsy
Detection of prostate cancer by MR-ultrasound fusion guided biopsy Poster No.: C-0761 Congress: ECR 2014 Type: Scientific Exhibit Authors: T. Durmus, C. Stephan, T. Slowinski, A. Thomas, A. Maxeiner, B.
More informationHypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings
Hypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings Hak Jong Lee, MD 1 Ghee Young Choe, MD 2 Chang Gyu Seong, MD 3 Seung Hyup Kim, MD 4 Index terms: Prostate Prostate,
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationIntroduction. HP Beerlage 1 *, RG Aarnink 1, ETh Ruijter 2, JA Witjes 1, H Wijkstra 1, CA van de Kaa 2, FMJ Debruyne 1 & JJMCH de la Rosette 1
(2001) 4, 56±62 ß 2001 Nature Publishing Group All rights reserved 1365±7852/01 $15.00 www.nature.com/pcan Correlation of transrectal ultrasound, computer analysis of transrectal ultrasound and histopathology
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationThe Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend
www.kjurology.org http://dx.doi.org/1.4111/kju.212.53.1.686 Urological Oncology The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend Hyung-Sang
More informationIntroduction. Objective To investigate the clinical significance of the 1.13 ng/ml, P<0.001) and a lower free-to-total PSA
British Journal of Urology (1998), 81, 532 538 Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA
More informationOriginal Paper. Urol Int 2013;90: DOI: /
Urologia Internationalis Original Paper Received: January 27, 2012 Accepted after revision: November 26, 2012 Published online: February 13, 2013 Comparison of Transrectal Prostate Biopsy Results with
More informationSafety and Efficacy of Combined Transrectal Ultrasound-Guided Prostate Needle Biopsy and Transurethral Resection of the Prostate
www.kjurology.org DOI:10.4111/kju.2010.51.2.101 Urological Oncology Safety and Efficacy of Combined Transrectal Ultrasound-Guided Prostate Needle Biopsy and Transurethral Resection of the Prostate Jeong
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/21761
More informationProstate specific antigen and acinar density: a new dimension, the Prostatocrit
ORIGINAL ARTICLE Vol. 43 (2): 230-238, March - April, 2017 doi: 10.1590/S1677-5538.IBJU.2016.0145 Prostate specific antigen and acinar density: a new dimension, the Prostatocrit Simon Robinson 1, Marc
More informationDeveloping a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection
DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong
More informationORIGINAL ARTICLES P ATIE TS A D METHODS. In patients with a PSA > 50 ng/ml, where no pathology RESULTS
-----.- SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER C F Heyns, A M audt'!, G Ahmed, H B Stopforth, G A Stellmacher, A J Visser Introduction. To determine
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationProstate Specific Antigen in a Community-Based Sample of Men Without Prostate Cancer: Correlations With Prostate Volume, Age, Body
The Prostate 27:24 1-249 (I 995) Prostate Specific Antigen in a Community-Based Sample of Men Without Prostate Cancer: Correlations With Prostate Volume, Age, Body Mass Index, and Symptoms of Prostatism
More informationUse of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate From Benign Prostatic Disease A Prospective Multicenter Clinical Trial William J. Catalona, MD; Alan W. Partin,
More informationof Nebraska - Lincoln
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Veterans Affairs Staff Publications U.S. Department of Veterans Affairs 8-2000 Detection, Characterization,
More informationThe Clinical Utility of Measuring Total PSA, PSA Density, γ-seminoprotein and γ-seminoprotein/total PSA in Prostate Cancer Prediction
Jpn J Clin Oncol 2000;30(8)337 342 Original Articles The Clinical Utility of Measuring Total PSA, PSA Density, γ-seminoprotein and γ-seminoprotein/total PSA in Prostate Cancer Prediction Ryusei Sasaki
More informationReal-time Elastography for the Diagnosis of Prostate Cancer: Evaluation of Elastographic Moving Images
Real-time Elastography for the Diagnosis of Prostate Cancer: Evaluation of Elastographic Moving Images Tomoaki Miyagawa 1, Masakazu Tsutsumi 2, Takeshi Matsumura 3, Natsui Kawazoe 2, Satoru Ishikawa 2,
More informationNomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
Original Article Prostate Int 2013;1(2):69-75 P R O S T A T E INTERNATIONAL Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
More information. ORIGINAL ARTICLES SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER
. SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER C F Heyns, AM Naude, G Ahmed, H B Stopforth, G A Stellmacher, A J Visser Introduction. To determine whether
More informationEffect of Dutasteride Therapy on Doppler US Evaluation of Prostate: Preliminary Results 1
Genitourinary Imaging Elizabeth P. Ives, MD Leonard G. Gomella, MD Ethan J. Halpern, MD Published online 10.1148/radiol.2371041543 2005; 237:197 201 Abbreviations: BPH benign prostatic hyperplasia PSA
More informationClinical Significance of Prostate Specific Antigen for Early Stage Prostate Cancer Detection
linical Significance of Prostate Specific Antigen for Early Stage Prostate ancer Detection Kyoichi Imai, Yoshio Ichinose, Yutaka Kubota, Hidetoshi Yamanaka, Jin Sato 2, Masahito Saitoh, Hiroki Watanabe
More informationUpgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy
MOLECULAR AND CLINICAL ONCOLOGY 2: 1145-1149 Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy CAROLINA D'ELIA, MARIA ANGELA CERRUTO, ANTONIO CIOFFI, GIOVANNI NOVELLA,
More informationOriginal Article INTRODUCTION. Abstract
Original Article DOI: 10.17354/ijss/2016/72 Prevalence of Prostatic Intraepithelial Neoplasia in Patients Diagnosed as Benign Prostatic Hyperplasia Underwent Transurethral Resection of the Prostate at
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationProspective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort
European Journal of Cancer (2012) 48, 1809 1815 Available at www.sciencedirect.com journal homepage: www.ejconline.com Prospective validation of a risk calculator which calculates the probability of a
More informationProstate cancer diagnosis: should patients with prostate specific antigen >10 ng/ml have stratified prostate biopsy protocols?
Cancer Detection and Prevention 32 (2009) 34 38 www.elsevier.com/locate/cdp Prostate cancer diagnosis: should patients with prostate specific antigen >0 ng/ml have stratified prostate biopsy protocols?
More informationDETERMINATION OF NORMAL RANGE OF ULTRASONIC SIZES OF PROSTATE IN OUR LOCAL ENVIRONMENT
DETERMINATION OF NORMAL RANGE OF ULTRASONIC SIZES OF PROSTATE IN OUR LOCAL ENVIRONMENT Marchie T.T, MBBS, FWACS, FICS, Diagnostic Urology Unit, Department Of Radiology, University Of Benin Teaching Hospital,
More informationUltrasound-guided transrectal extended prostate biopsy: a prospective study
DOI: 10.1111/j.1745-7262.2005.00019.x. Original Article. Ultrasound-guided transrectal extended prostate biopsy: a prospective study Mohammed Ahmed Al-Ghazo, Ibrahim Fathi Ghalayini, Ismail Ibrahim Matalka
More informationIs Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen?
www.kjurology.org http://dx.doi.org/1.4111/kju.1.3..8 Urological Oncology Is Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen? Jee
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationDiagnostic Value of Finger-guided Prostate Nodule Biopsy Combined With Systemic Random Biopsy
ORIGINAL ARTICLE Diagnostic Value of Finger-guided Prostate Nodule Biopsy Combined With Systemic Random Biopsy I-Ni Chiang, 1,2 Shang-Jen Chang, 3 Yeong-Shiau Pu, 1,2 Kuo-How Huang, 1,2 Hong-Jen Yu, 1,2
More informationLikelihood of Prostate Cancer Based on Prostate-Specific Antigen Density by MRI: Retrospective Analysis
Journal of Computer Assisted Tomography 26(3):432 437 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Likelihood of Prostate Cancer Based on Prostate-Specific Antigen Density by MRI: Retrospective
More informationAPPENDIX. Studies of Prostate-Specific Antigen for Prostate Cancer Screening and Early Detection
APPENDIX D Studies of Prostate-Specific Antigen for Prostate Cancer Screening and Early Detection APPENDIX D: STUDIES OF PROSTATE SPECIFIC ANTIGEN FOR PROSTATE CANCER SCREENING AND EARLY DETECTION: RESEARCH
More informationRESEARCH ARTICLE. Deep Par Kash 1, Murli Lal 1, Altaf Hussain Hashmi 1, Muhammed Mubarak 2 * Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.7.3087 RESEARCH ARTICLE Utility of Digital Rectal Examination, Serum Prostate Specific Antigen, and Transrectal Ultrasound in the Detection of Prostate Cancer:
More informationBJUI. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
. JOURNAL COMPILATION 2010 BJU INTERNATIONAL Urological Oncology FOLLOW-UP OF MEN WITH AN ELEVATED PCA3 SCORE AND A NEGATIVE BIOPSY REMZI ET AL. BJUI BJU INTERNATIONAL Follow-up of men with an elevated
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationTransrectal Ultrasound for Prostate Cancer: Perspectives from National Cheng Kung University Hospital
R E V I E W A R T I C L E Transrectal Ultrasound for Prostate Cancer: Perspectives from National Cheng Kung University Hospital Yuh-Shyan Tsai 1,2, Chia-Horng Chen 3, Yi-Hsiang Lin 4, Tzong-Shin Tzai 1
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationbj ct Prostate-Specific Antigen, Digital Rectal Examination, and Transrectal Ultrasonography: Their Roles in Diagnosing Early Prostate Cancer
bj ct * VI Prostate-Specific Antigen, Digital Rectal Examination, and Transrectal Ultrasonography: Their Roles in Diagnosing Early Prostate Cancer MICHAEL R. CUPP, M.D., JOSEPH E. OESTERLING, M.D., Department
More informationComparison Of Accuracy Of Prostate Model Volume Measurement Between 2 Dimensional And 3 Dimensional Ultrasonography.
ISPUB.COM The Internet Journal of Radiology Volume 14 Number 2 Comparison Of Accuracy Of Prostate Model Volume Measurement Between 2 Dimensional And 3 Dimensional Ultrasonography. S Park, S Hwang Citation
More informationSignificance of Atypical Small Acinar Proliferation and High-Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsy
www.kjurology.org http://dx.doi.org/1.4111/kju.211.52.11.736 Urological Oncology Significance of Atypical Small Acinar Proliferation and HighGrade Prostatic Intraepithelial Neoplasia in Prostate Biopsy
More informationKEY WORDS : Total Prostate Specific Antigen, Prostatic Acid Phosphatase, Benign Prostatic Hyperplasia, Prostate Cancer, and Sudanese.
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 3 Issue 1 January 2014 PP.36-40 Serum Total Prostatic Specific Antigen and Prostatic Acid
More informationDIAGNOSIS OF NONSPECIFIC GRANULOMATOUS PROSTATITIS IN PATIENTS UNDERGOING PROSTATE BIOPSY UNDER TRANSRECTAL ULTRASOUND GUIDANCE
32, 4, 2010, 3.,.. DIAGNOSIS OF NONSPECIFIC GRANULOMATOUS PROSTATITIS IN PATIENTS UNDERGOING PROSTATE BIOPSY UNDER TRANSRECTAL ULTRASOUND GUIDANCE N. Smilov, N. Koleva and I. Lozev Medical Institute Ministry
More information@Original Contribution
Pergamon Ultrasound in Med. & Biol., Vol. 21, No. 1, pp. 11-16, 1995 Copyright 0 1995 Elsevier Science Ltd P&ted in the USA. All rights reserved 0301.5629/95 $9.50 + 00 0301-5629(94)00084-O @Original Contribution
More informationCumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio
European Urology European Urology 45 (2004) 160 165 Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio Gunnar Aus a,*, Charlotte Becker b, Stefan
More informationPROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
More informationBJUI. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer
2008 The Authors. Journal compilation 2008 BJU International Original Article TEMPLATE-BASED PROSTATE BIOPSY SYSTEM MEGWALU et al. BJUI BJU INTERNATIONAL Evaluation of a novel precision template-guided
More informationCan Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?
Original Article Yonsei Med J 2015 Nov;56(6):1492-1496 pissn: 0513-5796 eissn: 1976-2437 Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?
More informationeuropean urology 55 (2009)
european urology 55 (2009) 385 393 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Is Prostate-Specific Antigen Velocity Selective for Clinically Significant
More informationTable 1. Descriptive characteristics, total prostate-specific antigen, and percentage of free/total prostate-specific antigen distribution Age Groups
Oncology Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort Umberto Capitanio, Paul Perrotte, Laurent Zini, Nazareno Suardi, Elie Antebi,
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationProstate Cancer Detection and High Grade PIN
Clinical Urology Prostate Cancer Detection and High Grade PIN International Braz J Urol Vol. 37 (1): 87-93, January - February, 2011 doi: 10.1590/S1677-55382011000700011 The Implication of Initial 24-Core
More informationOriginal Article. Introduction. Xin LIU 1, *Jie TANG 2, Xiang FEI 2, Qiu-Yang LI 2
Original Article Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less Xin LIU 1, *Jie TANG 2, Xiang
More informationORIGINAL ARTICLE Urology INTRODUCTION
ORIGINAL ARTICLE Urology DOI: 10.3346/jkms.2011.26.1.85 J Korean Med Sci 2011; 26: 85-91 Initial Biopsy Outcome Prediction in Korean Patients- Comparison of a Novel Web-based Korean Prostate Cancer Risk
More informationUse of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer { (2003) 6, 39 44 ß 2003 Nature Publishing Group All rights reserved 1365 7852/03 $25.00 www.nature.com/pcan
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationNomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/ml
ORIGINAL ARTICLE Oncology & Hematology http://dx.doi.org/10.3346/jkms.2014.29.3.338 J Korean Med Sci 2014; 29: 338-342 Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less
More informationLocalised carcinoma of the prostate: a
Postgrad Med J' 1997; 73: 691-696 G The Fellowship of Postgraduate Medicine, 1997 Management options Summary The incidence and prevalence of prostate cancer is increasing. A number of aetiological factors
More informationMRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review
MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationStatistically Optimized Biopsy Strategy for the Diagnosis of Prostate Cancer
Statistically Optimized Biopsy Strategy for the Diagnosis of Prostate Cancer Dinggang Shen 1, Zhiqiang Lao 1, Jianchao Zeng 2, Edward H. Herskovits 1, Gabor Fichtinger 3, Christos Davatzikos 1,3 1 Center
More informationSerum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study
european urology 51 (2007) 1645 1653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia Serum Prostate-Specific Antigen as a Predictor of Prostate
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationInpyeong Hwang, Sang Youn Kim, Jeong Yeon Cho, Myoung Seok Lee, Seung Hyup Kim
The diagnostic ability of an additional midline peripheral zone biopsy in transrectal ultrasonography-guided 12-core prostate biopsy to detect midline prostate cancer Inpyeong Hwang, Sang Youn Kim, Jeong
More informationElastic scattering spectroscopy for detection of prostate cancer: preliminary feasibility study
Elastic scattering spectroscopy for detection of prostate cancer: preliminary feasibility study Irving J. Bigio a*, Ousama A amar b and Michelle S. Hirsch c a,b Department of Biomedical Engineering and
More information